Concepedia

Fengjuan Xuan

FX

26

Publications

7.9K

Citations

21

H-Index

2008

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

University of Colorado Denver

National Jewish Health

Merck & Co., Inc., Rahway, NJ, USA (United States)

German Center for Lung Research

Fengjuan Xuan is an author at Vertex Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

2008–2024

26

Publications

26

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

, , +2

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 707 citations · Full text

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Jane C. Davies, Samuel M. Moskowitz, Cynthia D. Brown et al. · New England Journal of Medicine · 2018 · 320 citations · Full text

Rows per page

1–5 of 26